Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia

NCT05400317 is registered in ClinicalTrials.gov with Addpharma Inc. as lead sponsor.

NCT NCT05400317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05400317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia
Lead sponsor
Addpharma Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
July 27, 2022
Completion date
June 30, 2026
Enrollment
520 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mixed dyslipidemia